Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Cooper

Showing results (281-290 of 363) with videos related to

Pageof 37
Sort By:
Immunology and Cell Biology|April 1, 1995
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1J Corbeil, L A Evans, P W McQueen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteinsS C Meuer, J C Hodgdon, D A Cooper, et al.
The Journal of Nutrition|August 1, 1997
Olestra affects serum concentrations of alpha-tocopherol and carotenoids but not vitamin D or vitamin K status in free-living subjectsB P Koonsvitsky, D A Berry, M B Jones, et al.
The Journal of Infectious Diseases|September 5, 1998
Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modificationD Goldstein, P Hertzog, E Tomkinson, et al.
HIV Medicine|November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 21, 1998
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationshipP Vanhems, J Lambert, D A Cooper, et al.
Lancet (London, England)|March 9, 1985
Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversionD A Cooper, J Gold, P Maclean, et al.
Antiviral Research|August 26, 1998
Summary of the III International Consensus Symposium on Combined Antiviral TherapyJ W Cohen Stuart, C A Boucher, D A Cooper, et al.
AIDS Research and Human Retroviruses|February 14, 1998
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study GroupL J Ashton, A Carr, P H Cunningham, et al.
AIDS (London, England)|February 1, 1993
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative GroupD A Cooper, P O Pehrson, C Pedersen, et al.
Pageof 37

Showing results (281-290 of 363) with videos related to

Sort By:
Pageof 37
Immunology and Cell Biology|April 1, 1995
Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1J Corbeil, L A Evans, P W McQueen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1983
Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteinsS C Meuer, J C Hodgdon, D A Cooper, et al.
The Journal of Nutrition|August 1, 1997
Olestra affects serum concentrations of alpha-tocopherol and carotenoids but not vitamin D or vitamin K status in free-living subjectsB P Koonsvitsky, D A Berry, M B Jones, et al.
The Journal of Infectious Diseases|September 5, 1998
Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modificationD Goldstein, P Hertzog, E Tomkinson, et al.
HIV Medicine|November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 21, 1998
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationshipP Vanhems, J Lambert, D A Cooper, et al.
Lancet (London, England)|March 9, 1985
Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversionD A Cooper, J Gold, P Maclean, et al.
Antiviral Research|August 26, 1998
Summary of the III International Consensus Symposium on Combined Antiviral TherapyJ W Cohen Stuart, C A Boucher, D A Cooper, et al.
AIDS Research and Human Retroviruses|February 14, 1998
Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study GroupL J Ashton, A Carr, P H Cunningham, et al.
AIDS (London, England)|February 1, 1993
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative GroupD A Cooper, P O Pehrson, C Pedersen, et al.
Pageof 37